Simeprevir: Clinical Trials

18 trials of Simeprevir, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

17 completed, 1 terminated. 18 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 318Completed 17, Terminated 1

Follow Simeprevir: new trials by email Literature Review of Simeprevir trials Research Report on Simeprevir

Trials (filtered) newest first · largest first

All 18 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC
Sofosbuvir, Ribavirin, Simeprevir - Hepatitis C, Chronic, Hepatocellular Carcinoma
Phase 3CompletedNational Hepatology & Tropical Medicine Research Institute1502016-03-012026-04-13
Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis
Simeprivir (SMV), Sofosbuvir (SOF), Ribavirin (RBV) - Hepatitis C
Phase 3TerminatedUniversity of Colorado, Denver92015-05-012021-09-13
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection
Simeprevir, Sofosbuvir - Chronic Hepatitis C, Genotype 4 Chronic Hepatitis C
Phase 3CompletedJanssen R&D Ireland402015-01-012016-11-17
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis
Simeprevir, Sofosbuvir - Hepatitis C Virus Infection
Phase 3CompletedJanssen Infectious Diseases BVBA1032014-04-012016-04-04
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis
Simeprevir, Sofosbuvir - Hepatitis C Virus Infection
Phase 3CompletedJanssen Infectious Diseases BVBA3102014-04-012016-04-12
A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection
TMC435, Pegylated interferon alfa-2a (PegIFNα-2a), Ribavirin (RBV) - Hepatitis C, Chronic, Infection
Phase 3CompletedJanssen-Cilag International NV2322013-09-012016-09-21
An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients
TMC435, Peginterferon-alpha (PegIFNα-2a), Ribavirin (RBV) - Hepatitis C, Chronic
Phase 3CompletedJanssen R&D Ireland4572012-11-012015-08-13
A Study to Evaluate the Efficacy, Safety and Tolerability of TMC435 in Combination With PegIFN Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naïve or Treatment-Experienced, Chronic Hepatitis C Virus Genotype-4 Infected Patients
TMC435 - Hepatitis C
Phase 3CompletedJanssen R&D Ireland1072012-03-272017-07-07
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
TMC435, TVR - Hepatitis C
Phase 3CompletedJanssen R&D Ireland7712012-02-012016-04-26
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study
TMC435 - Hepatitis C
Phase 3CompletedJanssen R&D Ireland1422011-12-012016-04-04
A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1
TMC435, Pegylated interferon alpha-2a, Ribavirin - Hepatitis C Virus Genotype-1
Phase 3CompletedJanssen R&D Ireland1092011-10-012014-10-29
A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) Infection
TMC435, Peginterferon alfa-2b (pegIFN alfa-2b), Ribavirin (RBV) - Hepatitis C, Chronic
Phase 3CompletedJanssen Pharmaceutical K.K.792011-05-012014-05-05
An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants
Placebo, TMC435, Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b) - Hepatitis C
Phase 3CompletedJanssen R&D Ireland3932011-03-012014-06-13
A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected Patients
Placebo, TMC435, Peginterferon alfa-2a (pegIFN alfa-2a) - Hepatitis C, Chronic
Phase 3CompletedJanssen Pharmaceutical K.K.1832011-02-012014-01-17
A Phase III Study of TMC435 in Genotype 1, Hepatitis C-infected Participants Who Failed to Respond to Previous IFN-based Therapy
TMC435, Peginterferon alfa-2a (PegIFNα-2a ), Ribavirin (RBV) - Hepatitis C, Chronic
Phase 3CompletedJanssen Pharmaceutical K.K.1062011-02-012014-01-24
An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients
Placebo, TMC435, Peginterferon alpha-2a (PegIFN alpha-2a) - Hepatitis C
Phase 3CompletedJanssen R&D Ireland3952011-02-012014-06-04
An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy
TMC435, Placebo, Peginterferon alpha-2a (PegIFN alpha-2a) - Hepatitis C
Phase 3CompletedJanssen R&D Ireland3942011-02-012014-04-23
A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based Therapy
TMC435, Pegylated interferon (pegIFN alpha-2a), Ribavirin (RBV) - Hepatitis C, Chronic
Phase 3CompletedJanssen Pharmaceutical K.K.492011-01-012014-02-04

Conditions studied

Hepatitis C (13)  ·  Hepatitis C, Chronic (8)  ·  Fibrosis (2)  ·  Acquired Immunodeficiency Syndrome (1)  ·  Carcinoma, Hepatocellular (1)  ·  Infections (1)

Sponsors

Janssen R&D Ireland (9)  ·  Janssen Pharmaceutical K.K. (4)  ·  Janssen Infectious Diseases BVBA (2)  ·  Janssen-Cilag International NV (1)  ·  National Hepatology & Tropical Medicine Research Institute (1)  ·  University of Colorado, Denver (1)

Countries

United States (9)  ·  Spain (8)  ·  Canada (7)  ·  France (7)  ·  Germany (7)  ·  Belgium (6)  ·  Puerto Rico (6)  ·  United Kingdom (6)  ·  Austria (5)  ·  Australia (4)  ·  Japan (4)  ·  Poland (4)  ·  Portugal (4)  ·  Argentina (3)  ·  Brazil (3)

Top investigators

Aisha El Sharkawy, MD (1)  ·  Amanda Wieland, MD (1)  ·  Amr Maged (1)  ·  Gamal Esmat, MD. (1)  ·  Mai Mehrez, MD. (1)  ·  Mohamed Hassany, MD (1)

Results publications

PMID 25445400, PMID 17593061, PMID 17635375, PMID 17850410, PMID 18266997, PMID 19053983, PMID 24602923, PMID 24907224, PMID 24907225, PMID 25192745, PMID 25482330, PMID 25596313, PMID 26743093, PMID 26753774, PMID 26799692, PMID 27428331, PMID 27896822, PMID 28056030, PMID 28577353, PMID 29727383, PMID 8213790, PMID 9346731

NIH funding

2014 (1), UL1TR001082 (1)